BeOne Medicines (NASDAQ:ONC) Stock Price Down 3.6% Following Insider Selling

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) traded down 3.6% during trading on Thursday following insider selling activity. The company traded as low as $257.11 and last traded at $257.41. 165,301 shares changed hands during trading, a decline of 63% from the average session volume of 442,271 shares. The stock had previously closed at $267.13.

Specifically, CEO John Oyler sold 3,174 shares of BeOne Medicines stock in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $261.61, for a total transaction of $830,350.14. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Xiaodong Wang sold 2,007 shares of BeOne Medicines stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $265.50, for a total transaction of $532,858.50. The disclosure for this sale can be found here. In other BeOne Medicines news, COO Xiaobin Wu sold 1,363 shares of BeOne Medicines stock in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $260.00, for a total value of $354,380.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Analysts Set New Price Targets

ONC has been the topic of a number of research reports. Royal Bank Of Canada raised shares of BeOne Medicines from an "outperform" rating to a "moderate buy" rating and set a $311.00 price target on the stock in a research note on Friday. TD Securities reiterated a "buy" rating and issued a $334.00 price objective on shares of BeOne Medicines in a report on Thursday, April 24th. Sanford C. Bernstein set a $259.00 price objective on shares of BeOne Medicines in a report on Thursday, March 13th. Wall Street Zen upgraded shares of BeOne Medicines from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Finally, Bank of America upgraded shares of BeOne Medicines from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $207.00 to $320.00 in a report on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, BeOne Medicines presently has a consensus rating of "Buy" and an average price target of $320.67.

BeOne Medicines Price Performance

The stock's 50 day moving average is $247.90. The company has a quick ratio of 1.71, a current ratio of 1.96 and a debt-to-equity ratio of 0.05.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of ($0.71) by $1.93. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. On average, equities research analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current fiscal year.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.